FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
